Updated on 19 August 2014
WuXiPharmaTech passed inspection for API manufacturing base
Singapore: China-based WuXiPharmaTech, pharmaceutical, biotechnology and medical device research and development outsourcing company, has succesfully passed the US Food and Drug Administration (FDA) inspection for its Shanghai SynTheAll Pharmaceutical subisidiary for the manufacturing unit of active pharmaceutical ingredient (API) for a branded commercial drug.
"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr Ge Li, chairman and CEO of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."